Search Result

Results for "

RIPK1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (3) Autophagy (2) Bcr-Abl (1) Beclin1 (1) CDK (1) Cyclin G-associated Kinase (GAK) (1) Ferroptosis (1) HIV (1) IAP (1) LIM Kinase (LIMK) (1) MAP4K (1) MAPKAPK2 (MK2) (1) Mixed Lineage Kinase (2) Necroptosis (7) PROTACs (1) RIP kinase (38) Salt-inducible Kinase (SIK) (1) Ser/Thr Protease (1) Small Interfering RNA (siRNA) (3) ULK (1)
By Research Areas:	Cancer (9) Cardiovascular Disease (1) Infection (1) Inflammation/Immunology (32) Metabolic Disease (1) Neurological Disease (7)

Inhibitors & Agonists

Peptides

Recombinant Proteins

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-RS11992

RIPK1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
RIPK1 Human Pre-designed siRNA Set A contains three designed siRNAs for RIPK1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

RIPK1 Human Pre-designed siRNA Set A RIPK1 Human Pre-designed siRNA Set A

HY-RS11993

Ripk1 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Ripk1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ripk1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Ripk1 Mouse Pre-designed siRNA Set A Ripk1 Mouse Pre-designed siRNA Set A

HY-RS11994

Ripk1 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Ripk1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Ripk1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Ripk1 Rat Pre-designed siRNA Set A Ripk1 Rat Pre-designed siRNA Set A

HY-146757

RIPK1-IN-13	RIP kinase	Inflammation/Immunology
RIPK1-IN-13 (Compound 8) is a potent inhibitor of *RIPK1* with an IC₅₀ value of 1139 nM. RIPK1-IN-13 blocks the activation of the necroptosis pathway via the inhibition of RIPK1. RIPK1-IN-13 has the potential for the research of inflammation diseases ^[1].

HY-143480

RIPK1-IN-15	RIP kinase	Neurological Disease Inflammation/Immunology
RIPK1-IN-15 (Compound 2.5) is a potent inhibitor of *RIPK1. RIPK1*-IN-15 has the potential for the research neurodegenerative, autoimmune, and inflammatory diseases ^[1].

HY-146758

RIPK1-IN-14	RIP kinase	Neurological Disease Inflammation/Immunology
RIPK1-IN-14 (Compound 41) is a potent inhibitor of *RIPK1* with an IC₅₀ value of 92 nM. RIPK1-IN-14 shows a significant anti-necroptotic effect in a necroptosis model in U937 cells ^[1].

HY-143726

RIPK1-IN-8	RIP kinase	Inflammation/Immunology
RIPK1-IN-8 (example 16), an aminoimidazopyridine, is a potent and selective *RIPK1* inhibitor with an IC₅₀ of 4 nM. RIPK1-IN-8 has the potential for inflammatory diseases research ^[1].

HY-157039

RIPK1-IN-17	RIP kinase	Inflammation/Immunology
RIPK1/3-IN-17 (Compound 10) is a *RIPK1* and *RIPK3* inhibitor. RIPK1/3-IN-17 specifically inhibits necroptosis by inhibiting RIPK1, RIPK3, and MLKL phosphorylation ^[1].

HY-156367

RIPK1-IN-16	RIP kinase	Inflammation/Immunology
RIPK1-IN-16 is an orally active and potent inhibitor of *RIPK1. RIPK1-IN-16 inhibits excessive inflammation by blocking RIPK1-mediated necroptosis in vivo. RIPK1*-IN-16 protects mouse from TNF-induced systemic inflammatory response syndrome and sepsis ^[1].

HY-143727

RIPK1-IN-9	RIP kinase	Inflammation/Immunology
RIPK1-IN-9 (example 45), a dihydronaphthyridone compound, is a potent and selective *RIPK1* inhibitor. RIPK1-IN-9 inhibits U937 cell (IC₅₀=2 nM) and L929 cell (IC₅₀=1.3 nM) ^[1].

HY-157963

RIPK1-IN-23	RIP kinase Necroptosis	Inflammation/Immunology Cancer
RIPK1-IN-23 (compound 19) is a *RIPK1* inhibitor with potent anti-necroptotic effects in HT-29 cells (EC₅₀ of 1.7 nM). RIPK1-IN-23 shows anti-inflammatory activities ^[1].

HY-162097

RIPK1-IN-20	RIP kinase Necroptosis	Cancer
RIPK1-IN-20 (compound 13c) has a favorable RIPK1 kinase inhibition activity with an IC₅₀ value of 59.8 nM. RIPK1-IN-20 blocks TNFα-induced necroptosis in both human and murine cells (EC₅₀=1.06–4.58 nM) ^[1].

HY-160216A

RIPK1-IN-18 sulfate hydrate	RIP kinase	Inflammation/Immunology
RIPK1-IN-18 sulfate hydrate is a potent *RIPK1* inhibitor that can be used in autoimmune diseases research (NZ748385A; compound i) ^[1].

HY-144276

RIPK1-IN-11	RIP kinase	Inflammation/Immunology
RIPK1-IN-11 is a potent and orally active *RIPK1* inhibitor (K_d=9.2 nM; IC₅₀=67 nM). RIPK1-IN-11 inhibits necroptosis in both human and mouse cells (EC₅₀=17-30 nM). Anti-inflammatory activity ^[1].

HY-160216

RIPK1-IN-18

RIP kinase Inflammation/Immunology

RIPK1-IN-18 (compound i) is a potent inhibitor of RIPK1. RIPK1-IN-18 can be used in autoimmune diseases research ^[1].

RIPK1-IN-18	RIP kinase	Inflammation/Immunology
RIPK1-IN-18 (compound i) is a potent inhibitor of *RIPK1. RIPK1*-IN-18 can be used in autoimmune diseases research ^[1].

HY-144277

RIPK1-IN-12	RIP kinase Necroptosis	Inflammation/Immunology
RIPK1-IN-12 is a potent *RIPK1* inhibitor. RIPK1-IN-12 inhibits necroptosis in both human and mouse cells, with EC₅₀ values of 1.6 and 2.9 nM, respectively ^[1].

HY-157751

RIPK1-IN-21	RIP kinase	Neurological Disease Inflammation/Immunology
RIPK1-IN-21 (Compound I-5) is an inhibitor of *RIPK1* with an EC₅₀ value of 14.8 nM. RIPK1-IN-21 can be used in the research of neurodegenerative, autoimmune, and inflammatory diseases ^[1].

HY-119933

RIPK1-IN-7	RIP kinase	Cancer
RIPK1-IN-7 is a potent and selective *RIPK1* inhibitor with a K_d of 4 nM and an enzymatic IC₅₀ of 11 nM. RIPK1-IN-7 exhibits excellent antimetastasis activity in the experimental B16 melanoma lung metastasis model ^[1].

HY-143728

RIPK1-IN-10

RIP kinase Inflammation/Immunology

RIPK1-IN-10 is a potent RIPK1 inhibitor, example 37, extracted from patent WO2021160109 ^[1].

RIPK1-IN-10	RIP kinase	Inflammation/Immunology
RIPK1-IN-10 is a potent RIPK1 inhibitor, example 37, extracted from patent WO2021160109 ^[1].

HY-157456

RIPK1-IN-19	RIP kinase	Inflammation/Immunology
RIPK1-IN-19 (compound 10b) is a selective *RIPK1* inhibitor (IC₅₀=15 nM). RIPK1-IN-19 displays potent protective activity in TNFα-induced systemic inflammatory response syndrome (SIRS) model and Imiquimod (IMQ)-induced psoriasis model. RIPK1-IN-19 can be used in research on inflammation and immune system diseases ^[1].

HY-126296

RIPK1-IN-3

RIP kinase Inflammation/Immunology

RIPK1-IN-3 (Example 38), a RIPK1 inhibitor, extracted from patent WO2018148626A1, possesses anti-inflammatory proprieties ^[1].

RIPK1-IN-3	RIP kinase	Inflammation/Immunology
RIPK1-IN-3 (Example 38), a *RIPK1* inhibitor, extracted from patent WO2018148626A1, possesses anti-inflammatory proprieties ^[1].

HY-162237

RIPK1-IN-22	RIP kinase	Inflammation/Immunology
RIPK1-IN-13 (compound 28) is a selective inhibitor for receptor-interacting serine/threonine-protein kinase 1 (RIPK1), the inhibitory activity is measured by ADP-Glo Kinase Assay with a pK_i of 7.66. RIPK1-IN-13 inhibits human leukaemia cells U937 with a pIC₅₀ of 7.2 ^[1].

HY-18901

RIPK1-IN-4
RIPK1-IN-4 (compound 8) is a potent and selective type II kinase inhibitor of receptor interacting protein 1 (RIP1) kinase and binds to a DLG-out inactive form of RIP1 with an IC₅₀s of 16 nM and 10 nM for RIP1 and ADP-Glo kinase ^[1].

HY-132203

Necrostatin-34	RIP kinase	Inflammation/Immunology Cancer
Necrostatin-34 (Nec-34), a *RIPK1* kinase inhibitor, stabilizes RIPK1 kinase in an inactive conformation by occupying a distinct binding pocket in the kinase domain ^[1].

HY-161059

ZB-R-55

RIP kinase Infection

ZB-R-55 is an orally active RIPK1 inhibitor. ZB-R-55 can be used for sepsis study ^[1].

ZB-R-55	RIP kinase	Infection
ZB-R-55 is an orally active *RIPK1* inhibitor. ZB-R-55 can be used for sepsis study ^[1].

HY-14622A

Necrostatin 2 racemate 5+ Cited Publications Necrostatin 1S; Nec-1S; 7-Cl-O-Nec1	RIP kinase	Cancer
Necrostatin 2 racemate (Nec-1S), the Necrostatin-1 (HY-15760) stable, is a potent and specific *RIPK1* inhibitor lacking the IDO-targeting effect ^[1].

HY-148787

Oditrasertib	RIP kinase	Inflammation/Immunology
Oditrasertib is a receptor-interacting protein kinase 1 (RIPK1) inhibitor with an IC₅₀ value lower than 100 nM. Oditrasertib can be used for the research of diseases involving inflammation or cell death ^[1].

HY-149258

KWCN-41	Necroptosis RIP kinase Mixed Lineage Kinase	Inflammation/Immunology
KWCN-41 is a selective and efficient inhibitor of RIPK1 kinase with an IC₅₀ value of 88 nM. KWCN-41 specifically inhibits cell necrosis but does not inhibit apoptosis. KWCN-41 also has anti-inflammatory effects ^[1].

HY-151873

SZM679	RIP kinase	Inflammation/Immunology
SZM679 is a potent, orally active and selective *RIPK1* inhibitor with K_d values of 8.6 nM and >5000 nM for RIPK1 and RIPK3, respectively. SZM679 reverses the tumor necrosis factor-induced systemic inflammatory response. SZM679 decreases the Tau hyperphosphorylation, neuroinflammation, and the RIPK1 phosphorylation level in the hippocampus and cortex. SZM679 can be used in research of Alzheimer's disease (AD) ^[1].

HY-161060

Zharp1-211	RIP kinase	Inflammation/Immunology
Zharp1-211 is a potent inhibitor of RIPK1 kinase. Zharp1-211 significantly reduces the expression of *JAK/STAT1*-mediated chemokines and MHC class II molecules in intestinal epithelial cells ^[1].

HY-128348

PK68	RIP kinase	Inflammation/Immunology Cancer
PK68 is a potent orally active and specifical type II inhibitor of receptor-interacting kinase 1 (RIPK1) with an IC₅₀ of ~90 nM, displays inhibition of RIPK1-dependent necroptosis. PK68 powerfully ameliorates TNF-induced systemic inflammatory response syndrome, and can be used for the research of inflammatory disorders and cancer metastasis ^[1].

HY-148382

RI-962	RIP kinase Necroptosis	Neurological Disease Inflammation/Immunology
RI-962 is a potent and selective receptor-interacting protein kinase 1 (RIPK1) inhibitor. RI-962 inhibits RIPK1 with an IC₅₀ value of 35.0 nM. RI-962 can be used for the research of nervous system diseases and inflammatory diseases ^[1].

HY-148239

TP-030-2

RIP kinase Ser/Thr Protease Neurological Disease Inflammation/Immunology

TP-030-2 is a RIPK1 inhibitor (human K_i=0.43 nM; mouse IC₅₀=100 nM) ^[1] .

TP-030-2	RIP kinase Ser/Thr Protease	Neurological Disease Inflammation/Immunology
TP-030-2 is a *RIPK1* inhibitor (human K_i=0.43 nM; mouse IC₅₀=100 nM) ^[1] .

HY-138779

ICCB-19 hydrochloride	Autophagy RIP kinase Apoptosis	Inflammation/Immunology
ICCB-19 hydrochloride is a TRADD (TNFRSF1A associated via death domain) inhibitor. ICCB-19 hydrochloride binds with N-terminal domain of TRADD (TRADD-N), disrupting its binding to both TRADD-C and TRAF2. ICCB-19 hydrochloride is indirect inhibitor of RIPK1 kinase activity. ICCB-19 hydrochloride effectively induces autophagy and the degradation of long-lived proteins ^[1].

HY-114371

Eclitasertib DNL-758; SAR-443122	RIP kinase	Inflammation/Immunology
Eclitasertib (DNL-758) is a potent receptor-interacting protein kinase 1 (RIPK1) inhibitor with an IC₅₀ of <1 µΜ (From patent WO2017136727A2, example 42) ^[1].

HY-14622

Necrostatin 2 5 Publications Verification	RIP kinase	Cancer
Necrostatin 2 is a potent necroptosis inhibitor. EC₅₀ for inhibition of necroptosis in FADD-deficient Jurkat T cells treated with TNF-α is 0.05 μM. Necrostatin 2 is also a *RIPK1* inhibitor.

HY-114492

GSK547 GSK'547	RIP kinase	Cancer
GSK547 (GSK'547) is a highly selective and potent inhibitor of receptor-interacting serine/threonine protein kinase 1 (RIPK1), inhibits macrophage-mediated adaptive immune tolerance in pancreatic cancer ^[1].

HY-134050

Apostatin-1 Apt-1	RIP kinase Autophagy Apoptosis Beclin1 Necroptosis	Inflammation/Immunology
Apostatin-1 (Apt-1) is a potent TRADD inhibitor. Apostatin-1 can bind with TRADD-N (K_D=2.17 μM), disrupting its binding to both TRADD-C and TRAF2. Apostatin-1 modulates the ubiquitination of *RIPK1* and beclin 1. Apostatin-1 blocks apoptosis and restores cellular homeostasis by activating autophagy in cells with accumulated mutant tau, α-synuclein, or huntingtin ^[1].

HY-148253

TP-030-1	RIP kinase	Neurological Disease Inflammation/Immunology
TP-030-1 is an inhibitor of *RIPK1. TP-030-1 inhibits hRIPK1 with a K_i* value of 3.9 nM and inhibits mRIPK1 with an IC₅₀ value of 4.2 μM. TP-030-1 can be used for the research of inflammatory diseases and neurodegenerative diseases ^[1].

HY-149052

SZM-1209	RIP kinase Mixed Lineage Kinase Necroptosis	Inflammation/Immunology
SZM-1209 is an orally active, potent and specific *RIPK1* inhibitor, with a K_d of 85 nM. SZM-1209 exhibits high anti-necroptotic activity (EC₅₀=22.4 ± 8.1 nM). SZM-1209 shows anti-SIRS (systemic inflammatory response syndrome), and anti-ALI (acute lung injury) effects ^[1].

HY-131064

RIPK3-IN-1 1 Publications Verification	RIP kinase	Inflammation/Immunology
RIPK3-IN-1 is a *RIPK3* type II DFG-out inhibitor with an IC₅₀ of 9.1 nM. RIPK3-IN-1 inhibits RIPK1 and RIPK2 with IC₅₀s of 5.5 and >10 μM. RIPK3-IN-1 is also a c-Met kinase inhibitor with an IC₅₀ of 1.1 μM ^[1].

HY-151369

AV123	RIP kinase	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
AV123 (compound 12) is a non-cytotoxic *RIPK1* inhibitor (IC₅₀=12.12 µM). AV123 blocks the TNF-α-induced necroptotic (EC₅₀=1.7 μM) but not the apoptotic cell death. AV123 can be used in the study of necrotic chronic conditions such as ischemia-reperfusion injury of the brain, heart and kidney, inflammatory diseases, neurodegenerative diseases and infectious diseases ^[1].

HY-16591

Birinapant Maximum Cited Publications 25 Publications Verification TL32711	IAP Apoptosis HIV	Cancer
Birinapant (TL32711), a bivalent Smac mimetic, is a potent antagonist for XIAP and *cIAP1* with K_ds of 45 nM and less than 1 nM, respectively. Birinapant (TL32711) induces the autoubiquitylation and proteasomal degradation of cIAP1 and cIAP2 in intact cells, which results in formation of a RIPK1: caspase-8 complex, caspase-8 activation, and induction of tumor cell death. Birinapant (TL32711) targets TRAF2-associated cIAPs and abrogates TNF-induced NF-κB activation.

HY-148061

DB1113	PROTACs Bcr-Abl CDK Salt-inducible Kinase (SIK) Cyclin G-associated Kinase (GAK) MAP4K MAPKAPK2 (MK2) Ferroptosis ULK LIM Kinase (LIMK)	Others
DB1113 (Example 24) is a bifunctional compound targeted protein degradation of kinases. DB1113 degrades ABL1, ABL2, BLK, CDK11B, CDK4, CSK, EPHA3, FER, GAK, LIMK1, MAP3K20, MAP4K1, MAP4K2, MAP4K3, MAP4K5, MAPK14, MAPK7, MAPK8, MAPK9, MAPKAPK2, MAPKAPK3, NLK, PDIK1L, PTK2B, RIPK1, RPS6KA1, RPS6KA3, SIK2, SIK3, STK35, TNK2, and ULK1. DB1113 can be used for research of disease or disorder mediated by aberrant kinase activity ^[1].

Cat. No.	Product Name	Target	Research Area

HY-144277

RIPK1-IN-12	RIP kinase Necroptosis	Inflammation/Immunology
RIPK1-IN-12 is a potent *RIPK1* inhibitor. RIPK1-IN-12 inhibits necroptosis in both human and mouse cells, with EC₅₀ values of 1.6 and 2.9 nM, respectively ^[1].

Species:	Human (2)
Tag:	His (1) Tag Free (1) GST (1)
Source:	Sf9 insect cells (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P701767

	RIPK1 Protein, Human (Sf9) RIPK1; Receptor-interacting serine/threonine-protein kinase 1; Cell death protein RIP; Receptor-interacting protein 1; RIP-1	Human	Sf9 insect cells
	RIPK1 protein is a serine-threonine kinase that centrally regulates TNF-mediated apoptosis, necroptosis, and inflammatory pathways. Functionally, it plays a kinase-dependent role in the regulation of cell death and a kinase-independent scaffolding function in the control of inflammatory signaling and cell survival. RIPK1 Protein, Human (Sf9) is the recombinant human-derived RIPK1 protein, expressed by Sf9 insect cells , with tag free. The total length of RIPK1 Protein, Human (Sf9) is 327 a.a., .

HY-P701768

	RIPK1 Protein, Human (Sf9, His, GST) RIPK1; Receptor-interacting serine/threonine-protein kinase 1; Cell death protein RIP; Receptor-interacting protein 1; RIP-1	Human	Sf9 insect cells
	RIPK1 protein is a serine-threonine kinase that centrally regulates TNF-mediated apoptosis, necroptosis, and inflammatory pathways. Functionally, it plays a kinase-dependent role in the regulation of cell death and a kinase-independent scaffolding function in the control of inflammatory signaling and cell survival. RIPK1 Protein, Human (Sf9, His, GST) is the recombinant human-derived RIPK1 protein, expressed by Sf9 insect cells , with N-8*His, N-GST labeled tag. The total length of RIPK1 Protein, Human (Sf9, His, GST) is 327 a.a., .

Cat. No.	Product Name	Application	Reactivity

HY-P81539

p-RIPK1(S166) Antibody (YA1284)

Cell death protein RIP,Receptor-interacting protein 1
WB, IHC-F, IHC-P, FC, ICC/IF, IP Human, Mouse, Rat

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote